TY - JOUR
T1 - Immune-mediated approaches against COVID-19
AU - Florindo, Helena F.
AU - Kleiner, Ron
AU - Vaskovich-Koubi, Daniella
AU - Acúrcio, Rita C.
AU - Carreira, Barbara
AU - Yeini, Eilam
AU - Tiram, Galia
AU - Liubomirski, Yulia
AU - Satchi-Fainaro, Ronit
N1 - Publisher Copyright:
© 2020, Springer Nature Limited.
PY - 2020/8/1
Y1 - 2020/8/1
N2 - The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The long incubation period of this new virus, which is mostly asymptomatic yet contagious, is a key reason for its rapid spread across the world. Currently, there is no worldwide-approved treatment for COVID-19. Therefore, the clinical and scientific communities have joint efforts to reduce the severe impact of the outbreak. Research on previous emerging infectious diseases have created valuable knowledge that is being exploited for drug repurposing and accelerated vaccine development. Nevertheless, it is important to generate knowledge on SARS-CoV-2 mechanisms of infection and its impact on host immunity, to guide the design of COVID-19 specific therapeutics and vaccines suitable for mass immunization. Nanoscale delivery systems are expected to play a paramount role in the success of these prophylactic and therapeutic approaches. This Review provides an overview of SARS-CoV-2 pathogenesis and examines immune-mediated approaches currently explored for COVID-19 treatments, with an emphasis on nanotechnological tools.
AB - The coronavirus disease-19 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The long incubation period of this new virus, which is mostly asymptomatic yet contagious, is a key reason for its rapid spread across the world. Currently, there is no worldwide-approved treatment for COVID-19. Therefore, the clinical and scientific communities have joint efforts to reduce the severe impact of the outbreak. Research on previous emerging infectious diseases have created valuable knowledge that is being exploited for drug repurposing and accelerated vaccine development. Nevertheless, it is important to generate knowledge on SARS-CoV-2 mechanisms of infection and its impact on host immunity, to guide the design of COVID-19 specific therapeutics and vaccines suitable for mass immunization. Nanoscale delivery systems are expected to play a paramount role in the success of these prophylactic and therapeutic approaches. This Review provides an overview of SARS-CoV-2 pathogenesis and examines immune-mediated approaches currently explored for COVID-19 treatments, with an emphasis on nanotechnological tools.
UR - http://www.scopus.com/inward/record.url?scp=85087808917&partnerID=8YFLogxK
U2 - 10.1038/s41565-020-0732-3
DO - 10.1038/s41565-020-0732-3
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???
C2 - 32661375
AN - SCOPUS:85087808917
SN - 1748-3387
VL - 15
SP - 630
EP - 645
JO - Nature Nanotechnology
JF - Nature Nanotechnology
IS - 8
ER -
